Current Project 3
Back to current projects overview
Background: Hypertension (HT) comes about through interaction between genetic, environmental and life-style factors. However, the literature on the presumed associations between genetic variability and HT is conflicting and difficult to interpret because of unstandardized definitions, divergent epidemiological methods and insufficient sample size.
Objective: EPOGH sets out (1) to measure the genetic determination of blood pressure (BP) and HT and its cardiovascular complications; (2) to identify polymorphisms significantly associated with HT or cardiovascular risk; (3) to produce a database, which describes the genetic background and cardiovascular phenotypes of 4 Eastern and 2 Western European populations; (4) and to establish a permanent pool of genetic material, which is immediately accessible to address emerging issues in genetic research.
Methodology: Via random population sampling and enrolment at specialized HT clinics, EPOGH will recruit 600 nuclear families (nearly 2400 subjects) in 6 European countries (
Expected outcomes: HT affects 15% of the adult European population. Beyond age 65, its complications explain over 50% of total mortality. This project will enable the pharmaceutical industry to develop, produce and commercialize simple diagnostic tests to determine genetic predisposition and responsiveness to drug treatment. This, in turn, will lead to the more rational prevention and treatment of HT and its incapacitating complications and will help to curb the epidemic of cardiovascular disease in